Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BSTO I like the write up they did on BSTO, also like this "With over 1 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our new Publisher Alert: Blue Star Opportunities (BSTO) the share price is only going to rise!"
The more eyes on this stock the better for the current shareholders,
regardless, I'm patient, this stock is going to fly sooner or later!
BSTO Previous clients include General Motors, Siemens, Ford World Headquarters all on the DuroDesign Flooring Commercial Client List
BSTO Love this..."We continue to expand our network of company-owned (Duro Design) factory outlets throughout North America and will have a retail presence in America's top 20 markets by the end of 2015."
BSTO Picked up some nice cheapies today, I'm in!
Good call, UP 43.84% today
From the Atlanta Business Chronicle "The Hilton Atlanta Northeast and the Atlanta Marriott Norcross were purchased by investment company ASAP International Holdings Inc. Both properties are expected to get major renovations in the coming months." April 25th 2014
Look for PR's on coming upgrades to these already classy hotels from ASAE.
ASAE Nice info, good DD
ASAE Just needs some volume
ASAE Making money a very good sign
ASAE Love the low float
ASAE I also really like this stock, could pop at anytime
ARGL Great quote, hopefully ARGL's 2yr expansion plan currently underway will start yielding some great PR's SOON
ARGL Keep the faith, great UNDERVALUED stock, will fly with volume!
ARGL Just a matter of time before this breaks 40 cents then 50 cents then break out to dollarland. Great company, great prospects, great management and great share structure with a SUPER LOW float.
ARGL This looks like it is getting ready to run, very thin level 2 with super low float
ARGL This looks like it is getting ready to run, very thin level 2 with super low float
ARGL Starting to move UP, way way undervalued
PTEO Biotech with new multi million dollar partnership, very thin level 2 getting ready break out
PTEO Biotech with new multi million dollar partnership, very thin level 2 getting ready break out
ARGL___Going to start moving UP VERY SOON!
ARGL FLOAT + "But here is something very few people know. That float is outdated. An insider has purchased about a million shares and the ACTUAL float is only about
1.5 million." Yikes, this stock will move on AIR!!!
ARGL SIX different business divisions and they are the LARGEST company of their kind in the US.
ARGL Annual revenues in the 70 to 80 million range...monster in the making here!
ARGL Wow, what a find!!
"TOP REASONS TO BUY Proteo (PTEO) NOW
PTEO has had ORPHAN drug status granted for for it's lead drug Tiprelestat (Elafin) BOTH in the European Union AND the United States.
(Orphan drug status is a VERY GOOD status to receive, Proteo (PTEO) received it on BOTH continents from the FDA and their European counterparts the EMA)
On May 20th 2014, Proteo (PTEO) signed an agreement with Biotech Development Corp. (BDC) who gave them total funds of EURO 3.5 million (approx. US$ 4.8 million) in return for a share of future revenues for Tiprelestat (Elafin).
(Wow, you only ante up that kind of money if you are VERY CONFIDENT APPROVAL for drug is coming!)
In February 2014, Proteo (PTEO) received Protocol Assistance (scientific advice for orphan medicines) from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) with respect to the strategy for further clinical development and marketing authorization for Tiprelestat (Elafin)
(There's the answer, the European Medicines Agency (EMA) is taking them under their wing and helping guide them toward APPROVAL. No wonder Biotech Development Corp. was eager to ink a multi million dollar deal with Proteo!!!....It really helps when the regulatory agency helps walk you through the process toward APPROVAL. Remember this company is ONLY going to invest all those millions if they believe that APPROVAL from the EMA is coming, they invested and for the rest of us that is a HUGE BUY SIGNAL!!)
With a LOW FLOAT of just 11.4 Million shares Proteo (PTEO) is under the radar and the share price is likely to move up quickly as news of the company spreads.
Amazingly the share price of Proteo (PTEO) is around .09 cents, the positive news has not yet caught up with the share price, BUT IT WILL, now is the time to BUY Proteo (PTEO) BEFORE the share price takes off!!
Proteo (PTEO) through it's wholly owned subsidiary, Proteo Biotech AG, that is a German corporation is a clinical stage biotech drug development company focusing on the development of anti-inflammatory treatments for rare diseases with significant unmet needs. Proteo (PTEO) intends to develop, promote and market pharmaceuticals and other biotech products.
Proteo (PTEO) lead product is Tiprelestat (Elafin) that prevents acute postoperative inflammatory complications. Tiprelestat (Elafin) ability to block the proteases that cause these undesirable effects makes it a promising drug for the treatment of various inflammatory diseases and post traumatic inflammatory complications.
Currently Tiprelestat (Elafin) is undergoing clinical trials for 3, yes..THREE different diseases:
Esophagus cancer surgery (Phase II completed, Phase III planning)
Coronary artery bypass surgery (Phase II ongoing)
Kidney transplantation (Phase II regulatory approval)
The excellent tolerability of Tiprelestat (Elafin) in human subjects has led to late stage clinical trials.
BUT IT GETS EVEN BETTER:
Proteo (PTEO) and it's Orphan Drug Designation:
In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as tax credits and extended exclusivity periods for the drug, all intended to encourage the development of drugs which might otherwise not have been developed.
Orphan Drug Designation has been awarded to the Proteo (PTEO) by the European Commission for the use of Tiprelestat (Elafin) in the treatment of esophagus carcinoma.
The U.S. Food and Drug Administration (FDA) has GRANTED orphan drug designation to Tiprelestat (Elafin) for the prevention of inflammatory complications of transthoracic esophagectomy AND for pulmonary arterial hypertension.
In February 2014, Proteo (PTEO) received Protocol Assistance (scientific advice for orphan medicines) from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) with respect to the strategy for further clinical development and marketing authorization for Tiprelestat (Elafin) when used for acute postoperative inflammatory complications after resection of esophageal cancer.
(Once again It really helps when the regulatory agency helps walk you through the process toward APPROVAL)
For the development of its lead product Tiprelestat (Elafin) Proteo (PTEO) has established a network of globally renowned research institutes, physicians and hospitals in the US and Europe. The development of Tiprelestat (Elafin) has been widely supported by public grants. Worldwide leading funding bodies, such as the American National Institutes of Health (NIH) and the British Medical Research Council (MRC), support preclinical and clinical studies on Tiprelestat (Elafin) with high volume grants.
(Most biotechs would be VERY ENVIOUS to have so many grants and major organisations paying for the research and development of their leading drug!)"
PTEO Break out coming, BIDS are starting to stack
PTEO Low float biotech with partnership news getting ready to break out, have to hit the ask to get filled
PTEO Low float biotech with partnership news getting ready to break out, have to hit the ask to get filled
PTEO The European Medicines Agency (EMA) is taking them under their wing and helping guide them toward APPROVAL. No wonder Biotech Development Corp. was eager to ink a multi million dollar deal with Proteo!!!....It really helps when the regulatory agency helps walk you through the process toward APPROVAL. Remember this company is ONLY going to invest all those millions if they believe that APPROVAL from the EMA is coming, they invested and for the rest of us that is a HUGE BUY SIGNAL!!)
PTEO Awesome news: On May 20th 2014, Proteo (PTEO) signed an agreement with Biotech Development Corp. (BDC) who gave them total funds of EURO 3.5 million (approx. US$ 4.8 million) in return for a share of future revenues for Tiprelestat (Elafin).
PTEO has ORPHAN drug status granted for for it's lead drug Tiprelestat (Elafin) BOTH in the European Union AND the United States
PTEO About to break out, low float with good news
VYST Since February 2014 there have been 19, YES (NINETEEN) separate INSIDER Buys recorded and filed with the SEC. For the rest of us on the outside that is a HUGE, HUGE BUY SIGNAL if ever there was one!
VYST Since February 2014 there have been 19, YES (NINETEEN) separate INSIDER Buys recorded and filed with the SEC. For the rest of us on the outside that is a HUGE, HUGE BUY SIGNAL if ever there was one!
VYST INSIDERS BUYING like crazy since February, low float !
VYST INSIDERS BUYING like crazy since February, low float !
VYST Top Reasons To Buy VYST NOW
"Vystar Corporation (VYST) with HEAVY Insider Buying!!
Vystar Corporation (VYST) has seen NUMEROUS insider buys so far in 2014, buy now like the insiders before the share price takes off!
Insiders Buying at Vystar Corporation (VYST):
Since February 2014 there have been 19 (NINETEEN) separate INSIDER Buys recorded and files with the SEC.
Ask yourself this, who knows more about the company, you or the insiders. Of course the insiders do and they are BUYING left and right.
For example:
-In March 2014 alone: 9 Insider Buys for 3 820 700 million shares
Dollar value of insider BUYING shares recorded in March alone: $130,919.00
-In April 2014: 4 Insider Buys for 40 500 shares
NO INSIDER SELLING!!
-Something BIG is coming, when insiders buy this often they do so for a REASON!
Once again ask yourself this, who knows more about the company, you or the insiders. Of course the insiders do and they are BUYING left and right.
Here are just some of the INSIDER BUYS at Vystar Corporation (VYST):
-A part owner purchased 40 500 shares -SEC Form 4 with a transaction dates of April 1st, 4th and 14th 2014
-The Chairman, President and CEO in March 2014 alone purchased 833 333 shares - SEC Form 4 with a transaction date of March 7th 2014
-Two different company Directors:
One Director purchased over 1 million shares, 1,666,667 shares to be exact -SEC Form 4 with a transaction date of March 4th 2014.
-Another Director purchased 833 333 shares -SEC Form 4 with a transaction date of February 27th 2014
-The same Director then purchased an additional 250 000 shares the next day -SEC Form 4 with a transaction date of February 28th 2014
-A Part Owner made FOUR separate Insider Buys for a total of 120 700 shares between the dates between March 17th and March 31st 2014 -SEC Form 4 with a transaction dates of March 17th, 18th, 20th and 31st 2014
-Earlier in the month the same part owner purchased 30 000 shares -SEC Form 4 with a transaction date of March 12th 2014
-The same part owner also purchased 1 000 000 (Yes 1 MILLION) shares a few days earlier -SEC Form 4 with a transaction date of March 7th 2014
-The same part owner also purchased 187 000 shares on March 3rd -SEC Form 4 with a transaction date of March 3rd 2014
-The same part owner also purchased 1 220 000 (Yes over I Million) shares during February 2014 - 4 different SEC Form 4 with a transaction dates In February 2014
GET THE PICTURE...... buy early like the insiders and then hang on and enjoy the ride. Big things coming!!
BUT IT GETS EVEN BETTER:
Vystar Corporation (VYST) is the exclusive creator of Vytex Natural Rubber Latex that can be used in over 40,000 products. Vystar Corporation (VYST) holds 4 patents for it's products in the United States and also has 5 International Patents!
A Joint Venture with UV Flu Technologies (UVFT) was PR'd in January 2014 after the Consumer Electronics Show...here are some comments and possible clues WHY the insiders are BUYING :
-"The global business contacts and opportunities generated at CES for both of our companies were excellent and far exceeded any previous efforts," stated Michael Ross, UVFT CEO. "We look forward to sharing details as contracts are finalized." - Michael Ross, UVFT CEO
-"The technologies attracted the attention of numerous new manufacturers and suppliers that have been actively seeking these solutions. Vystar and UVFT are now further exploring multiple business opportunities worldwide and have moved closer to finalizing multi-million dollar contracts with potential partners, manufacturers, suppliers and distributors." - (Michael Ross, UVFT CEO)
-Since this PR in January insider buying has been HUGE! No insider selling!"
VYST Something BIG is coming, when insiders buy this often they do so for a REASON!
Once again ask yourself this, who knows more about the company, you or the insiders. Of course the insiders do and they are BUYING left and right.
VYST BIG MOVE UP COMING...From an official press release dated January 14th 2014 "Vystar..now further exploring multiple business opportunities worldwide and have moved closer to finalizing multi-million dollar contracts with potential partners, manufacturers, suppliers and distributors"
Since this PR in January insider buying has been HUGE! No insider selling!